Immunotherapy
Finding ways to stimulate the body's immune system to help attack cancer cells is a growing area of research at The Institute of Cancer Research.
Clinical trials led by the ICR and our hospital partner The Royal Marsden have shown that the immunotherapy drug pembrolizumab can help extend the lives of some patients with advanced head and neck cancer, and prostate cancer.
The use of 'oncolytic' viruses, which can kill cancer cells both directly and by directing the immune system against them, is also an exciting area of research being explored by ICR researchers.
This page highlights recent news stories, blog posts and videos that concern immunotherapy research at the ICR.
Related pages
Latest ICR News
Breast cancer test predicts relapse risk in just two weeks – and could spare thousands of patients from unnecessary treatment
Thousands of women with breast cancer could be spared unnecessary treatment, thanks to a simple test which can identify whether or not their cancer is likely to return – just two weeks after starting treatment.
Targeted radiotherapy just as effective for low-risk breast cancer and reduces risk of side effects
Thousands of women who undergo radiotherapy for low-risk breast cancer could be spared some of the side effects of treatment after a study confirmed that more targeted treatments are just as effective at controlling the disease in the long term.